Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.42 |
| ▸ | ESR1 | P03372 | 6/20 | 0.42 |
| ▸ | ESRRB | O95718 | 1/20 | 0.42 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 2/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.41 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952866 | 0.86 | TRIM24 (0.47) | ESR2ESR1TYRTRIM24TRIM33 | |
| SCHEMBL7913737 | 0.86 | TRIM24 (0.47) | ESR2ESR1TYRTRIM24TRIM33 | |
| Resorcinol SCHEMBL27738320 | 0.78 | LMNA (0.50) | ESR2ESR1ESRRBESRRATRIM24 | |
| SCHEMBL27534432 | 0.76 | ESR2 (0.43) | ESR2ESR1ESRRBESRRATYR | |
| SCHEMBL28331091 | 0.76 | ALDH1A1 (0.41) | ALDH5A1ABATTDP1KDM4EALDH1A1 | |
| SCHEMBL22242785 | 0.75 | ESR2 (0.42) | ESR2ESR1ESRRBESRRATYR | |
| SCHEMBL30152425 | 0.75 | EGFR (0.47) | ESR2ESR1TDP1KDM4EALDH1A1 | |
| SCHEMBL29420732 | 0.75 | TYR (0.52) | ESR2ESR1ESRRBESRRATYR | |
| SCHEMBL686136 | 0.75 | TYR (0.52) | ESR2ESR1ESRRBESRRATYR | |
| SCHEMBL71628 | 0.75 | EGFR (0.47) | ESR2ESR1TDP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285778-B | Method for transparent modification of polypropylene by using DBS-like transparent modified polypropylene macromolecular nucleating agent | 杭州师范大学 | 2024-09-20 | — | — | CN | disclosed |
| CN-117285778-A | Method for transparent modification of polypropylene by using DBS-like transparent modified polypropylene macromolecular nucleating agent | 杭州师范大学 | 2023-12-26 | — | — | CN | disclosed |
| EP-1750706-B1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | Univ Virginia Patent Found (US) | 2016-10-05 | — | — | EP | disclosed |
| US-9133136-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133136-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-8642610-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642610-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-8298512-B2 | Methods of determining β-III tubulin expression | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-8298512-B2 | Methods of determining β-III tubulin expression | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-8178545-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178545-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-18 | — | — | US | disclosed |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-18 | — | — | US | disclosed |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-06-14 | — | — | US | disclosed |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | TP53, MAP2, MAP1LC3B | ESR2 3152/4885ESR1 3229/4885ESRRB 3333/4885 |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | TUBB3, TUBB1, TUBB | ESR2 3178/4885ESR1 4678/4885ESRRB 3077/4885 |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | TP53, MAP2, MAP1LC3B | ESR2 3152/4885ESR1 3229/4885ESRRB 3333/4885 |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | TP53, MAP2, MAP1LC3B | ESR2 3152/4885ESR1 3229/4885ESRRB 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.